@stocksavvyshayFeb 24, 2026 · 2:24 PM

@VanquishTrader $NVO needs to spend $15B and just buy out $VKTX already

@stocksavvyshayFeb 23, 2026 · 12:41 PM

@PolymarketMoney Hard not to wonder if $NVO should just bite the bullet and make a move on $VKTX at $100+.

@stocksavvyshayJan 5, 2026 · 3:12 PM

@PolymarketMoney $VKTX is my favorite name in this space

@adamfeuersteinNov 4, 2025 · 2:33 PM

@A_May_MD $VKTX longs https://t.co/G9KER8QOVM

@adamfeuersteinAug 19, 2025 · 11:34 AM

$VKTX - Mizuho's Jared Holz on the oral data: Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range but over 72-weeks. A much longer trial and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term. Pipeline and/or better versions needed to get investors and patients more interested. LLY could bounce a bit early but oral weight-loss programs continue to be highly controversial in terms of how they are perceived by the Street.